“You are only as good as the company you keep” also applies to therapeutics like AdAPT-001 – EpicentRx

by EpicentRx | Oct 17, 2023 | Media

Oncolytic Virotherapy Summit 2023

by EpicentRx | Sep 25, 2023 | Conferences

December 2023; Boston, MA Oral Presentation: Evaluating the Advantages & Hurdles of Intratumoral Delivery of Oncolytic Viruses

Severe Oral Mucositis: Companies Put Their Money where the Mouth is and Vie for a Marketshare

by EpicentRx | Sep 11, 2023 | Media

Inflammasome Therapeutics Summit

by EpicentRx | Sep 1, 2023 | Conferences

November 2023; Boston, Massachusetts Oral Presentation: The Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases

Neuroscience 2023

by EpicentRx | Sep 1, 2023 | Conferences

November 2023; Washington D.C. Oral Presentation: The CNS-permeable NLRP3 inhibitor RRx-001 is neuroprotective in experimental models of Parkinson’s disease